Open AccessВИЗНАЧЕННЯ ГЕНЕТИЧНОГО ПОЛІМОРФІЗМУ CYP2C9 НА ТЛІ ПРИЗНАЧЕННЯ ВАРФАРИНУ У ПАЦІЄНТІВ НА ІШЕМІЧНУ ХВОРОБУ СЕРЦЯ, УСКЛАДНЕНУ ПОСТІЙНОЮ ФОРМОЮ ФІБРИЛЯЦІЇ ПЕРЕДСЕРДЬ
Author(s) -
Панібратюк Ольга Анатоліївна,
Яковлева Ольга Олександрівна
Publication year - 2020
Publication title -
web of scholar/web of scholar
Language(s) - English
Resource type - Journals
eISSN - 2518-1688
pISSN - 2518-167X
DOI - 10.31435/rsglobal_wos/31012020/6888
Subject(s) - genotyping , cyp2c9 , allele , isozyme , genetics , mutation , biology , medicine , gene , genotype , biochemistry , enzyme
This article describes the results of a genetic study of the spread of CYP2C9 polymorphic variants in patients in the Podilskyi region of Ukraine. In different ethnic groups, the frequency of cytochrome polymorphic isoenzymes can vary significantly. The presence of genetic mutations of this cytochrome (Arg144Cys, Ile359Leu) is associated with an increased concentration of warfarin in the blood, which can lead to excessive hypocoagulation and risk of bleeding. Particular attention should be paid to patients with a detected mutation in homozygous form, as both alleles of the gene are mutant (their carriers are "slow metabolizers" and therefore require more careful dose selection). Patients are advised to undergo individual genotyping, which will help to predict the risk of each individual patient.